#### APPENDICES

#### Appendix 1 - Flow chart of literature search



#### Appendix 2. Characteristics of cohorts included in the review

| Study Code | Reference | Year of report | Facilities (n) | Sector | Years of cohort enrollment | Number started on ART (n) | Median age (years) | Female (%) | Starting CD4+ count\* |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| *Africa* |  |  |  |  |  |  |  |  |  |
| Botswana 1 | Bussmann1 | 2008 | 1 | Public | 2002 | 633 | 35 | 60% | 67 |
| Botswana 2 | Farahani2 | 2014 |  | Public | 2002-2010 | 102,713 | 35 | 63% | 151 |
| Burkina Faso 1 | Harries3 | 2010 | 1 | Public | 2002-2008 | 4,255 | 35 | 69% | 128 |
| Burkina Faso 2 | Kouanda4 | 2012 | 16 | Public | 2003-2008 | 5,608 |  | 70% | 124 |
| Burkina Faso 3 | Meda5 | 2013 | 2 |  | 2005-2010 | 867 | 36 | 70% | 152 |
| Cameroon 1 | Abessolo6 | 2011 | 1 | Public | 2009 | 600 |  |  |  |
| Cameroon 2a | Ngolle7 | 2011 | 1 | Public | 2006 | 330 |  |  |  |
| Cameroon 2b | Ngolle7 | 2011 | 1 | Public | 2008 | 295 |  |  |  |
| Cameroon 3 | Sieleunou8 | 2009 | 1 | Public | 2001-2006 | 1,187 | 35 | 44% | 105 |
| Cameroon 4 | Mosoko9 | 2011 | 1 | Public | 2002-2005 | 2,920 | 35 | 62% | 107 |
| Cameroon 5 | Billong10 | 2013 | 1 |  | 2009-2011 | 141 | 35 | 70% | 125 |
| Cote d'Ivoire 1 | Messou11 | 2011 | 3 | Public | 2006-2007 | 1,573 | 36 | 75% | 148 |
| Cote d'Ivoire 2 | Toure12 | 2008 | 19 | Public/private | 2004-2007 | 10,211 | 36 | 70% | 123 |
| Cote d'Ivoire 4 | CDC13 | 2013 |  |  | 2004-2007 | 3,682 | 36 | 66% | 143 |
| Cote d'Ivoire 5 | Abo14 | 2013 | 1 | Public | 2003-2008 | 1,008 | 35 | 67% | 186 |
| Cote d'Ivoire 3 | Ekouevi15 | 2010 | 1 |  | 2003-2005 | 247 | 28 | 100% | 188 |
| DRC 2 | Kitenge-Lubangi16 | 2008 | 3 | Private | 2002-2007 | 68 |  |  |  |
| DRC 1 | Koole17 | 2012 | 6 |  | 2005-2009 | 1,450 | 40 | 66% | 150 |
| Ethiopia 1 | Reda18 | 2013 | 3 |  | 2005-2008 | 1,540 | 32 | 63% | 135 |
| Ethiopia 2 | Balcha19 | 2010 | 5 | Public | 2006-2007 | 1,709 | 33 | 59% | 130 |
| Ethiopia 3 | Biadgilign20 | 2012 |  |  | 2005-2008 | 1,537 | 32 | 63% | 135 |
| Ethiopia 4 | Assefa21 | 2011 | 55 | Public/private | 2006-2008 | 37,466 |  |  |  |
| Ethiopia 5 | Gugsa22 | 2008 | 1 | Public | 2005 | 321 |  | 59% | 111 |
| Ethiopia 6 | Mulissa23 | 2010 | 1 | Public | 2003-2008 | 1,428 | 34 | 53% | 156 |
| Gambia 1 | Peterson24 | 2011 | 1 | Public | 2004-2009 | 308 | 35 | 67% | 110 |
| Ghana 1 | Sarfo25 | 2013 | 1 |  | 2004-2010 | 3,054 | 38 | 67% | 133 |
| Ghana 2 | Barlow-Mosha26 | 2012 |  |  | 2008 | 290 | 39 | 64% | 183 |
| Ghana 3 | Okyere27 | 2013 | 2 | Public | 2009-2012 | 91 | 35 | 59% | 161 |
| Guinea Bissau 1 | Honge28  | 2013 | 1 | Public | 2005-2012 | 2,351 | 38 | 66% |  |
| Kenya 1 | Chung29 | 2009 | 1 | FBO | 2004-2006 | 1,307 | 36 | 61% | 95 |
| Kenya 2a | Larson30 | 2013 | 1 | Public | 2007 | 120 |  |  | 98 |
| Kenya 2b | Larson30 | 2013 | 1 | Private | 2007 | 120 |  |  | 143 |
| Kenya 2c | Larson30 | 2013 | 1 |  | 2007 | 120 |  |  | 117 |
| Kenya 3 | Unge31  | 2009 | 1 | FBO | 2005-2007 | 830 | 35 | 65% | 203 |
| Kenya 4 | Achieng32 | 2012 | 6 |  | 2009-2010 | 301 | 37 | 70% | 170 |
| Kenya 5 | Ng'ang'a33 | 2012 |  |  | 2003-2010 | 1,676 | 34 | 65% |  |
| Lesotho 1 | Asiimwe34 | 2009 | 15 | Workplace | 2006-2008 | 3,394 |  | 94% | 173 |
| Lesotho 2 | Cohen35 | 2009 | 15 | Public | 2006-2008 | 4,064 |  |  |  |
| Lesotho 3 | Labhardt36 | 2013 | 2 | Public | 2008-2011 | 3,747 |  |  |  |
| Malawi 1 | Rasschaert37 | 2012 |  |  | 2003-2008 | 12,004 | 35 | 64% |  |
| Malawi 2a | Le Paih38 | 2009 |  | Public | 2001-2002 | 397 |  |  | 110 |
| Malawi 2b | Le Paih38 | 2009 |  | Public | 2002-2003 | 1,868 |  |  | 120 |
| Malawi 2c | Le Paih38 | 2009 |  | Public | 2003-2004 | 2,142 |  |  | 143 |
| Malawi 2d | Le Paih38 | 2009 |  | Public | 2004-2005 | 1,893 |  |  | 128 |
| Malawi 2e | Le Paih38 | 2009 |  | Public | 2005-2006 | 3,164 |  |  | 146 |
| Malawi 2f | Le Paih38 | 2009 |  | Public | 2006-2007 | 1,264 |  |  | 143 |
| Malawi 2g | Le Paih38 | 2009 |  | Public | 2007-2008 | 6,994 |  |  | 176 |
| Malawi 3 | Jahn39 | 2010 | 339 | Public | 2004-2009 | 253,154 |  |  |  |
| Morocco 1 | Brinkhof40 | 2008 |  |  | <2000-2004 | 412 | 35 | 46% | 108 |
| Mozambique 1 | Palladino41 | 2013 | 16 | Private | 2002-2006 | 142 |  | 42% | 185 |
| Mozambique 2 | Lambdin42 | 2011 | 18 | Public | 2006-2008 | 11,793 |  | 57% |  |
| Mozambique 3 | Micek43 | 2009 | 2 | Public | 2004-2005 | 471 |  |  |  |
| Mozambique 4 | Ehmer44 | 2011 |  |  | 2006 | 2,005 | 34 | 58% | 234 |
| Mozambique 5 | Moon45 | 2012 |  |  | 2006-2011 | 7,636 | 33 | 61% |  |
| Mozambique 6 | CDC13 | 2013 |  |  | 2004-2007 | 2,596 | 34 | 61% | 153 |
| Mozambique 7 | Wandeler46 | 2012 | 2 | Public | 2005-2010 | 1,417 | 32 | 58% | 233 |
| Mozambique 8 | Shepherd47 | 2013 |  | Public | 2006-2011 | 9,692 | 33 | 60% | 184 |
| Nigeria 1 | Odafe48 | 2012 | 10 | Public | 2007-2010 | 4,785 | 34 | 59% | 152 |
| Nigeria 2 | Onoka49 | 2012 | 2 | Public/private | 2008 | 1,034 | 37 | 61% | 170 |
| Nigeria 3 | Charurat50 | 2010 | 5 | Public | 2005-2006 | 5,760 | 35 | 59% | 121 |
| Nigeria 4 | Akinwande51 | 2011 | 31 |  | 2009-2010 | 12,764 |  |  | 177 |
| Rwanda 1 | Franke52 | 2013 | 4 | Public | 2007-2008 | 306 | 37 | 66% | 218 |
| Senegal 1 | Diouf53 | 2011 |  |  | 1998-2002 | 403 | 37 | 55% | 128 |
| South Africa 01 | Nglazi54 | 2011 | 1 | Public | 2002-2008 | 3,162 | 34 | 67% | 104 |
| South Africa 02 | Fatti55 | 2012 | 17 | Public | 2004-2010 | 47,285 | 35 | 68% | 122 |
| South Africa 03 | Kranzer56 | 2010 | 1 | Public | 2004-2009 | 1,154 | 32 | 65% | 122 |
| South Africa 04 | Buhlungu57 | 2008 | 1 |  | 2002-2004 | 226 |  | 73% |  |
| South Africa 05 | Dahab58 | 2011 | 1 | Public | 2005-2007 | 267 | 37 | 64% |  |
| South Africa 06 | Innes59 | 2012 | 72 | Private | 2005-2008 | 9,102 | 34 | 62% | 123 |
| South Africa 07 | Peltzer60 | 2011 | 3 | Public | 2007-2008 | 735 | 36 | 71% | 119 |
| South Africa 08 | Searle61 | 2009 | 1 | Public | 2004-2008 | 2,102 |  | 65% |  |
| South Africa 09 | Hoffmann62 | 2011 | 279 | Public/private | 2003-2008 | 15,060 | 38 | 36% | 127 |
| South Africa 10 | Osler63 | 2009 |  | Public | 2004-2008 | 49,383 |  | 69% |  |
| South Africa 11 | Evans64 | 2013 | 7 | Public | 2004-2010 | 40,176 |  | 63% | 105 |
| South Africa 12 | Van Cutsem65 | 2011 | 3 | Public | 2001-2007 | 6,411 | 32 | 68% | 99 |
| South Africa 13 | Clouse66 | 2013 | 1 | NGO | 2010 | 1,380 |  | 70% | 183 |
| South Africa 14 | MacPherson67 | 2009 | 1 | Public | 2005-2007 | 1,353 | 37 | 67% | 93 |
| South Africa 15 | Barth68 | 2008 | 1 | NGO | 2003-2006 | 609 | 35 | 71% | 67 |
| South Africa 16a | Fox69 | 2012 | 1 | Public | 2004-2005 | 1,794 | 35 | 69% | 82 |
| South Africa 16b | Fox69 | 2012 | 1 | Public | 2005-2006 | 2,154 | 35 | 67% | 90 |
| South Africa 16c | Fox69 | 2012 | 1 | Public | 2006-2007 | 2,617 | 36 | 64% | 84 |
| South Africa 16d | Fox69 | 2012 | 1 | Public | 2007-2008 | 1,996 | 36 | 61% | 82 |
| South Africa 16e | Fox69 | 2012 | 1 | Public | 2008-2009 | 2,185 | 37 | 63% | 99 |
| South Africa 16f | Fox69 | 2012 | 1 | Public | 2009-2010 | 2,481 | 37 | 58% | 114 |
| South Africa 17 | Khan70 | 2009 | 1 | Public | 2004-2005 | 684 |  | 73% |  |
| South Africa 18 | Ojikutu71 | 2008 | 1 | Semi-private | 1999-2004 | 309 | 38 | 56% | 65 |
| South Africa 19 | Vella72 | 2010 | 32 | Public | 2004-2006 | 2,835 | 34 | 67% |  |
| South Africa 20 | Nachega73 | 2008 |  | Private | 1998-2004 | 2,817 | 37 | 63% | 147 |
| South Africa 21 | Mutevedzi74 | 2013 | 17 | Public | 2004-2011 | 4,674 | 34 | 71% | 129 |
| South Africa 22 | Ahonkhai75 | 2012 | 71 | FBO/NGO | 2004-2008 | 11,397 | 35 | 67% | 101 |
| Swaziland 1 | Takuva76 | 2013 | 1 | Public  | 2006-2007 | 769 | 36 | 67% | 115 |
| Swaziland 2 | CDC13 | 2013 |  |  | 2004-2010 | 2,510 | 34 | 65% | 147 |
| Tanzania 1 | Mossdorf77 | 2011 | 1 | Public | 2005-2008 | 1,463 | 40 | 65% | 131 |
| Tanzania 2 | Kilama78 | 2013 | 348 | Public | 2004-2010 | 255,143 |  | 65% |  |
| Tanzania 3 | Johannessen79 | 2008 | 1 | FBO | 2003-2006 | 320 | 35 | 70% |  |
| Tanzania 4 | Hawkins80 | 2011 | 12 | Public | 2004-2008 | 12,842 | 37 | 66% | 131 |
| Tanzania 5 | CDC13 | 2013 |  |  | 2004-2009 | 1,458 | 36 | 67% | 132 |
| Togo 1 | Saka81  | 2013 | 28 |  | 2008-2011 | 16,617 | 32 | 62% | 119 |
| Uganda 1 | Bajunirwe82 | 2009 | 1 | Public | 2004-2006 | 399 | 38 | 60% |  |
| Uganda 2 | Funk83 | 2012 | 1 | Public | 2004-2011 | 8,835 | 31 | 63% | 172 |
| Uganda 3 | Geng84 | 2011 | 1 | Public | 2004-2007 | 3,628 | 35 | 61% | 95 |
| Uganda 4 | Mills85 | 2011 |  | Public | 2000-2010 | 22,315 | 27 | 69% | 142 |
| Uganda 5 | Kiragga86 | 2013 | 1 |  | 2005-2007 | 5,633 |  |  | 93 |
| Uganda 6 | Mudiope87 | 2013 | 1 |  | 2003-2010 | 289 | 29 | 100% | 176 |
| Uganda 7 | Burkey88 | 2013 | 1 |  | 2003-2005 | 1,763 | 36 | 71% |  |
| Uganda 8 | Namuwenge89 | 2012 | 201 | Public | 2010 | 27,425 |  |  |  |
| Uganda 9 | CDC13 | 2013 |  |  | 2004-2009 | 1,472 | 35 | 65% | 138 |
| Zambia 1 | Torpey90 | 2008 |  |  | 2005-2006 | 3,902 |  |  |  |
| Zambia 2 | Schoni-Affolter91 | 2011 | 68 | Public | 2004-2008 | 89,339 | 35 | 61% | 147 |
| Zambia 3 | Moyo92 | 2011 | 3 | Public | 2007-2010 | 1,084 |  | 57% |  |
| Zambia 4 | CDC13 | 2013 |  |  | 2004-2009 | 1,457 | 35 | 60% | 134 |
| Zimbabwe 1 | Bygrave93 | 2012 | 25 | Public | 2005-2008 | 592 | 26 | 82% | 111 |
| Zimbabwe 2 | Mutasa-Apollo94 | 2014 | 40 | Public | 2007-2009 | 3,919 | 37 | 64% | 121 |
| Zimbabwe 3 | Wandeler46 | 2012 | 2 | Public | 2005-2010 | 3,030 | 39 | 68% | 109 |
| Africa region (114 cohorts) |  |  |  | **1,128,210** | **35** | **65%** | **134** |
| *Asia* |  |  |  |  |  |  |  |  |  |
| Cambodia 2 | van Griensven95 | 2011 | 1 | Public | 2003-2010 | 2,840 | 30 | 53% | 78 |
| Cambodia 3 | Argemi96 | 2012 | 1 | Public | 2004-2009 | 1,010 | 40 | 50% | 83 |
| Cambodia 4 | Morineau97 | 2009 | 1 | Public | 2005-2007 | 549 | 34 | 53% | 69 |
| Cambodia 1 | Pujades-Rodriguez98 | 2011 | 1 | Public | 2002-2003 | 467 | 34 | 40% | 16 |
| China 1 | Zhu99 | 2012 |  | Public | 2003-2010 | 67,732 | 38 | 37% | 131 |
| China 2 | Spillane100 | 2012 |  |  | 2003-2009 | 1,014 | 34 | 34% | 91 |
| India 1 | McMahon101 | 2013 | 1 | Public/private | 2009-2010 | 230 | 38 | 39% | 146 |
| India 2a | Hingankar102 | 2012 | 1 |  | 2008 | 150 | 36 | 38% |  |
| India 2b | Hingankar102 | 2012 | 1 |  | 2007 | 148 | 37 | 38% |  |
| India 3 | Sharma103 | 2010 | 1 | Public | 2005-2006 | 631 | 36 | 20% | 110 |
| India 4 | Rewari104 | 2008 | 3 | Public | 2004-2005 | 972 | 35 | 34% | 119 |
| India 5 | Brinkhof40 | 2008 |  |  | <2000-2004 | 717 | 35 | 46% | 83 |
| India 6 | Rai105 | 2013 | 1 | Public | 2007 | 239 | 35 | 24% | 118 |
| India 7 | Ghate106 | 2013 |  | Public | 2005-2008 | 142 | 32 | 40% | 109 |
| India 8a | Chadha107 | 2013 | 1 |  | 2007-2010 | 43 | 33 | 48% | 108 |
| India 8b | Chadha107 | 2013 | 1 |  | 2007-2010 | 44 | 33 | 48% | 311 |
| India 8c | Chadha107 | 2013 | 1 |  | 2007-2010 | 43 | 33 | 48% | 584 |
| India 9 | Alvarez-Uria108 | 2013 |  | NGO | 2007-2011 | 3,159 | 34 | 41% | 140 |
| Indonesia | Wisaksana109 | 2009 | 1 |  | 1996-2008 | 96 | 29 | 9% | 115 |
| Laos 1 | Bastard110 | 2013 |  | Public | 2003-2009 | 913 | 32 | 44% | 49 |
| Myanmar 1 | Sabapathy111 | 2012 | 10 |  | 2003-2007 | 5,963 | 33 | 39% | 71 |
| Nepal 1 | Bhatta112 | 2013 | 5 | Public | 2006-2011 | 1,049 | 35 | 49% | 149 |
| Papua New Guinea 1 | Das113 | 2013 | 1 | Public | 2006-2010 | 993 |  | 63% | 158 |
| Thailand 1 | Brinkhof40 | 2008 |  |  | <2000-2004 | 36 | 35 | 46% | 121 |
| Thailand 2 | Ruxrungtham114 | 2013 | 1001 | Public | 2000-2012 | 213,753 | 36 | 48% | 130 |
| Vietnam 1 | Le115 | 2012 | 3 | Public | 2008 | 466 |  | 56% | 95 |
| Vietnam 2 | Duong116 | 2010 | 27 | Public | 2005-2008 | 11,432 |  |  |  |
| Vietnam 3 | Nguyen117 | 2013 | 30 | Public | 2005-2009 | 1,604 | 29 | 57% | 78 |
| Asia region (28 cohorts) |  |  |  |  |  **316,435**  | **34** | **42%** | **130** |
| *LAC* |  |  |  |  |  |  |  |  |  |
| Brazil 1 | Brinkhof40 | 2008 |  |  | <2000-2004 | 541 | 35 | 46% | 166 |
| Brazil 2 | Brinkhof40 | 2008 |  |  | <2000-2004 | 516 | 35 | 46% | 161 |
| Brazil 3 | Tuboi118 | 2009 |  |  | 1996-2007 | 522 | 37 | 34% | 153 |
| Brazil 4 | Cardoso119 | 2010 | 1 | Public | 1996-2006 | 702 | 36 | 35% |  |
| Dominican Republic 1 | Koenig120 | 2012 |  |  | 1998-2008 | 1,207 | 38 | 52% | 96 |
| Guyana 1 | Halpern121 | 2010 |  | Public | 2002 | 25 |  |  |  |
| Haiti 1 | Koenig120 | 2012 |  |  | 1998-2008 | 4,717 | 38 | 54% | 122 |
| Honduras 1 | Tuboi118 | 2009 |  |  | 1996-2007 | 328 | 37 | 39% | 105 |
| Jamaica 1 | Koenig120 | 2012 |  |  | 1998-2008 | 476 | 38 | 48% | 123 |
| Nicaragua 1 | Shakir122 | 2010 | 1 |  | 2005-2010 | 166 | 29 | 42% |  |
| Peru 1 | Tuboi118 | 2009 |  |  | 1996-2007 | 873 | 34 | 30% | 79 |
| Peru 2 | Munoz123 | 2010 |  | Public | 2005-2007 | 55 | 32 | 53% | 110 |
| LAC region (12 cohorts) |  |  |  |  | **10,128** | **25** | **44%** | **124** |  |
| Total (154 cohorts) |  |  |  |  | **1,554,773** | **35** | **58%** | **132** |  |

**Appendix 3. Definitions of loss to follow-up used by the studies included in the review**

|  |  |
| --- | --- |
| **Study code** | **Definition of loss to follow-up** |
| Botswana 2 | Did not return to a treatment centre for >90 days |
| Brazil 1 | Last follow-up visit occurred during first 6 months after starting ART |
| Brazil 2 | Last follow-up visit occurred during first 6 months after starting ART |
| Brazil 3 | Status (alive or dead) 365 days after HAART initiation was not known and if their last visit occurred more than 365 days before the closing date of the database |
| Brazil 4 | Missed three consecutive visits or did not return before the end of the study period |
| Burkina Faso 1 | Did not attend the clinic for 1month or more after their scheduled follow-up appointment |
| Cambodia 2 | Not presenting at the hospital for 6 months |
| Cambodia 4 | Did not attend the clinic for 2 consecutive months |
| Cambodia 1 | Missed their last clinical appointment by 2 months or more |
| Cameroon 3 | Did not return for >3 months  |
| Cameroon 4 | Failed to return for last scheduled clinic visit and not seen within 91 days prior to the end date of 31 December 2005 |
| China 1 | Not having a visit for at least 210 days |
| China 2 | Missing an appointment by more than 3 months on the date of analysis |
| Cote d'Ivoire 1 | Last contact was <month 12; not known to be dead or transferred out before month 12 and no information on their vital status |
| Cote d'Ivoire 2 | Last contact was >= 3months while not known to be dead or transferred out |
| Cote d'Ivoire 4 | Not attended the facility in the 90 days preceding data abstraction |
| Cote d'Ivoire 5 | Last contact was prior to 31 Dec 2008, and who were not found to be deceased, alive, or transferred out up to August 31st 2009 |
| Dominican Republic 1 | No visit within 6 months of the closing date of the database |
| Ethiopia 2 | Late for last appointment by >= 3 months |
| Ethiopia 6 | Did not attend the hospital within the previous 30 days |
| Gambia 1 | Not attended the clinic for at least 3 months after their last scheduled appointment |
| Ghana 3 | Not defined |
| Guinea Bissau 1 | Not visited the clinic for 90 days (60 days after the next appointment) |
| Haiti 1 | Not known to be dead and had at least 1 visit within 6 months of the closing date of the database |
| Honduras 1 | Vital status 365 days after HAART initiation not known and last visit occurred > 365 days before closing date of the database |
| India 1 | Vital status could not be ascertained and had not attended the clinic or picked up ART within 90 days of their last missed appointment |
| India 5 | Last follow-up visit occurred during the first 6 months after starting ART |
| India 7 | Did not collect drugs at their scheduled visits |
| Indonesia | Not returning for > 3 months without confirmation of death or transfer |
| Jamaica 1 | Not known to be dead and no visit within 6 months of the closing date of the database |
| Kenya 2a | > 3 months late for scheduled appointment closest to the end of month 12 |
| Kenya 2b | > 3 months late for scheduled appointment closest to the end of month 12 |
| Kenya 2c | > 3 months late for scheduled appointment closest to the end of month 12 |
| Kenya 3 | Not showed up 90 days after the last prescribed dose |
| Kenya 4 | Not appearing for any treatment activities for 90 days and inability to find the subject |
| Lesotho 3 | Not returning to the facility for >= six months after at least one visit, and not being reported dead or transferred out |
| Malawi 1 | Not attended the clinic for 3 months since the last scheduled appointment date |
| Morocco 1 | Last follow-up visit occurred during the first 6 months after starting ART |
| Mozambique 2 | Failed to return for treatment for 2 months beyond their missed ART refill visit for reasons unrelated to death |
| Mozambique 6 | Not returning to the facility in the 90 days preceding data abstraction |
| Mozambique 7 | Not returning to the facility for 6 months or longer |
| Mozambique 8 | > 6 months late for a visit or medication pickup |
| Myanmar 1 | > 60 days from last appointment |
| Nigeria 1 | Failed to return to the clinic after 90 days from their expected clinic appointment date |
| Nigeria 2 | Missed three clinic visits or medication pick- up |
| Nigeria 3 | Did not return to the clinic more than 60 days from their last expected visit |
| Peru 1 | Last visit occurred more than 365 days before the closing date of the database and status uknown |
| Rwanda 1 | Not returned to the clinic for at least 60 consecutive days |
| South Africa 02 | No visits to the clinic occurred for 180 days or more |
| South Africa 03 | Stopped ART for more than 30 days and had not returned to care at the time of censoring |
| South Africa 05 | Missed 6-month ART clinic visit by >= 1 month |
| South Africa 06 | Had not presented for 6 months after the last visit and were not known to have died |
| South Africa 07 | Missing the 6- and/or 12-month scheduled study follow-up appointment and missed the clinic appointment for two consecutive months |
| South Africa 11 | Missed a clinic appointment by >=3 months after the scheduled visit date |
| South Africa 12 | Patients were considered as LTF if their last clinic visit occurred at least 6 months before the end of the observation period (31 December 2007) |
| South Africa 13 | Not returning to the clinic within 3 months of the patient’s last missed scheduled visit |
| South Africa 14 | Patients who could not be traced and did not subsequently return to the clinic during the study period |
| South Africa 16a | >= 3 months late for a scheduled visit with no later visit |
| South Africa 16b | >= 3 months late for a scheduled visit with no later visit |
| South Africa 16c | >= 3 months late for a scheduled visit with no later visit |
| South Africa 16d | >= 3 months late for a scheduled visit with no later visit |
| South Africa 16e | >= 3 months late for a scheduled visit with no later visit |
| South Africa 16f | >= 3 months late for a scheduled visit with no later visit |
| South Africa 17 | Failure to collect ARVs was considered attrition |
| South Africa 18 | Did not return to the clinic within 6 months of the conclusion of the study |
| South Africa 19 | Last visit occurred more than 3 months before July 1, 2007 |
| South Africa 21 | No clinic visit for 180 day |
| South Africa 22 | No follow-up visits between 30 and 400 days after ART initiation |
| Swaziland 2 | Not attended the facility in the 90 days preceding data abstraction for either medication refill or a clinician visit |
| Tanzania 1 | Not showing up on two consecutive visits, i.e. for a period of 6 months |
| Tanzania 4 | No clinic visit or ART refills for >3 months |
| Tanzania 5 | Not attended the facility in the 90 days preceding data abstraction for either medication refill or a clinician visit |
| Thailand 1 | Last follow-up visit occurred during the first 6 months after starting ART |
| Togo 1 | No evidence that patient had died or moved four months after the last visit |
| Uganda 2 | Have not attended the clinic for 12 months |
| Uganda 3 | 3 months after expected return visit |
| Uganda 7 | No clinic visits over a final 90-day period in patients previously on ART without reported death or known transfer of care |
| Uganda 9 | Not attended the facility in the 90 days preceding data abstraction for either medication refill or a clinician visit |
| Vietnam 3 | Had not presented to the clinic for more than 90 days since their last recorded visit |
| Zambia 2 | > 14 months late for their most recent clinical or pharmacy visit |
| Zambia 4 | Not attended the facility in the 90 days preceding data abstraction for either medication refill or a clinician visit |
| Zimbabwe 1 | Non-attendance for a period of three months after the last ART prescription had been completed |
| Zimbabwe 3 | Not returning to the facility for >= 6 months |

**Appendix 4. Weighted average attrition by duration of reporting**

 

**Appendix 5. Sensitivity analysis: best case, worst case, and midpoint case scenarios**

****

**Supplemental References**

1 Bussmann H, Wester CW, Ndwapi N, *et al.* Five-year outcomes of initial patients treated in Botswana’s National Antiretroviral Treatment Program. *AIDS* 2008; **22**: 2303–11.

2 Farahani M, Vable A, Lebelonyane R, *et al.* Outcomes of the Botswana national HIV/AIDS treatment programme from 2002 to 2010: a longitudinal analysis. *Lancet Glob Heal* 2014; **2**: e44–50.

3 Harries K, Zachariah R, Manzi M, *et al.* Baseline characteristics, response to and outcome of antiretroviral therapy among patients with HIV-1, HIV-2 and dual infection in Burkina Faso. *Trans R Soc Trop Med Hyg* 2010; **104**: 154–61.

4 Kouanda S, Meda IB, Nikiema L, *et al.* Determinants and causes of mortality in HIV-infected patients receiving antiretroviral therapy in Burkina Faso: a five-year retrospective cohort study. *AIDS Care* 2012; **24**: 478–90.

5 Meda N, Sanou S, Dahourou D, *et al.* Community­ based organizations (CBO) HIV treatment programmes in urban Burkina Faso: initial mortality and its predictors. *IAS 2013 Conf* 2013; **MOPE188**: 1–2.

6 Abessolo Abessolo H. Application of WHO recommendations on biological monitoring of HIV-infected patients on ART in Yaoundé: it is not just matter of availability. *6th IAS Conf HIV Pathog Treat* 2011; **CDD038**.

7 Ngolle M. Free antiretroviral drugs contributes to reduced mortality, treatment interruptions and lost to follow up in an urban hospital in Yaoundé, Cameroon. *6th IAS Conf HIV Pathog Treat* 2011; **MOPE483**.

8 Sieleunou I, Souleymanou M, Schönenberger A-M, Menten J, Boelaert M. Determinants of survival in AIDS patients on antiretroviral therapy in a rural centre in the Far-North Province, Cameroon. *Trop Med Int Health* 2009; **14**: 36–43.

9 Mosoko JJ, Akam W, Weidle PJ, *et al.* Retention in an antiretroviral therapy programme during an era of decreasing drug cost in Limbe, Cameroon. *J Int AIDS Soc* 2011; **14**: 32.

10 Billong SC, Fokam J, Aghokeng AF, *et al.* Population-based monitoring of emerging HIV-1 drug resistance on antiretroviral therapy and associated factors in a sentinel site in Cameroon: low levels of resistance but poor programmatic performance. *PLoS One* 2013; **8**: e72680.

11 Messou E, Chaix M, Gabillard D, *et al.* Association between medication possession ratio, virologic failure and drug resistance in HIV-1 infected adults on antiretroviral therapy in Côte d’Ivoire. *JAIDS* 2011; **56**: 356–64.

12 Toure S, Kouadio B, Seyler C, *et al.* Rapid scaling-up of antiretroviral therapy in 10 000 adults in Cote d’Ivoire: 2-year outcomes and determinants. *AIDS* 2008; **22**: 873–82.

13 Centers for Disease Control. Differences Between HIV-Infected Men and Women in Antiretroviral Therapy Outcomes—Six African Countries, 2004–2012. *Morb Mortal Wkly Rep* 2013; **62**: 2002–11.

14 Abo Y, Minga A, Menan H, *et al.* Incidence of serious morbidity in HIV-infected adults on antiretroviral therapy in a West African care centre, 2003-2008. *BMC Infect Dis* 2013; **13**: 607.

15 Ekouevi DK, Coffie P a, Chaix M-L, *et al.* Immunological response to highly active antiretroviral therapy following treatment for prevention of mother to child transmission of HIV-1: a study in Côte d’Ivoire. *J Int AIDS Soc* 2010; **13**: 28.

16 Kitenge Lubangi K. Patient retention in workplace ART programs. Case analysis of Bralima/DRC since the inception in 2002 of the HAART treatment. *AIDS 2008 - XVII Int AIDS Conf* 2008; **CDC0592**.

17 Koole O, Kalenga L, Kiumbu M, *et al.* Retention in a NGO supported antiretroviral program in the Democratic Republic of Congo. *PLoS One* 2012; **7**: e40971.

18 Reda A a, Biadgilign S, Deribew A, Gebre B, Deribe K. Predictors of change in CD4 lymphocyte count and weight among HIV infected patients on anti-retroviral treatment in Ethiopia: a retrospective longitudinal study. *PLoS One* 2013; **8**: e58595.

19 Balcha TT, Jeppsson A. Outcomes of antiretroviral treatment: a comparison between hospitals and health centers in Ethiopia. *J Int Assoc Physicians AIDS Care (Chic)* 2010; **9**: 318–24.

20 Biadgilign S, Reda A a, Digaffe T. Predictors of mortality among HIV infected patients taking antiretroviral treatment in Ethiopia: a retrospective cohort study. *AIDS Res Ther* 2012; **9**: 15.

21 Assefa Y, Kiflie A, Tesfaye D, *et al.* Outcomes of antiretroviral treatment program in Ethiopia: retention of patients in care is a major challenge and varies across health facilities. *BMC Health Serv Res* 2011; **11**: 81.

22 Gugsa S. Determinants of retention and mortality during 6-month follow-up after initiation of HAART in an Ethiopian public HIV treatment program. *AIDS 2008 - XVII Int AIDS Conf* 2008; **CDB0246**.

23 Mulissa Z, Jerene D, Lindtjørn B. Patients present earlier and survival has improved, but pre-ART attrition is high in a six-year HIV cohort data from Ethiopia. *PLoS One* 2010; **5**: e13268.

24 Peterson I, Togun O, de Silva T, *et al.* Mortality and immunovirological outcomes on antiretroviral therapy in HIV-1 and HIV-2-infected individuals in the Gambia. *AIDS* 2011; **25**: 2167–75.

25 Sarfo FS, Keegan R, Appiah L, *et al.* High prevalence of renal dysfunction and association with risk of death amongst HIV-infected Ghanaians. *J Infect* 2013; **67**: 43–50.

26 Barlow-Mosha LN, Bagenda DS, Mudiope PK, *et al.* The long-term effectiveness of generic adult fixed-dose combination antiretroviral therapy for HIV-infected Ugandan children. *Afr Health Sci* 2012; **12**: 249–58.

27 Okyere GA, Alalbil PA, Ping-Naah H, Tifere Y. Determinants of Survival in Adult HIV Clients on Antiretroviral Therapy in Lawra and Jirapa Districts of Upper West Region, Ghana. *J Int Assoc Provid AIDS Care* 2013. doi:10.1177/2325957413500531.

28 Hønge BL, Jespersen S, Nordentoft PB, *et al.* Loss to follow-up occurs at all stages in the diagnostic and follow-up period among HIV-infected patients in Guinea-Bissau: a 7-year retrospective cohort study. *BMJ Open* 2013; **3**: e003499.

29 Chung MH, Drake AL, Richardson BA, *et al.* Impact of Prior HAART Use on Clinical Outcomes in a Large Kenyan HIV Treatment Program. *Curr HIV/AIDS Res* 2009; **7**: 441–6.

30 Larson BA, Bii M, Henly-thomas S, *et al.* ART treatment costs and retention in care in Kenya: a cohort study in three rural outpatient clinics. *J Int AIDS Soc* 2013; **16**: 18026.

31 Unge C, Södergård B, Ekström AM, *et al.* Challenges for scaling up ART in a resource-limited setting: a retrospective study in Kibera, Kenya. *J Acquir Immune Defic Syndr* 2009; **50**: 397–402.

32 Achieng L, Musangi H, Ong’uti S, *et al.* An observational cohort comparison of facilitators of retention in care and adherence to anti-eetroviral therapy at an HIV treatment center in Kenya. *PLoS One* 2012; **7**: e32727.

33 Ng’ang'a L. Long-term retention and predictors of loss to follow-up in an antiretroviral therapy program in an urban slum in Kenya. *19th Int AIDS Conf* 2012; **TUPE741**.

34 Asiimwe F. Rapid scale up of an industry wide workplace ART program in Lesotho through private public partnership. *5th IAS Conf HIV Pathog Treat* 2009; **MOPED030**.

35 Cohen R. Nurse-driven, community-supported HIV/AIDS care and treatment: 2 year antiretroviral treatment outcomes from a primary care level programme in rural Lesotho. *5th IAS Conf HIV Pathog Treat* 2009; **MOAD102**.

36 Labhardt ND, Keiser O, Sello M, *et al.* Outcomes of antiretroviral treatment programmes in rural Lesotho: health centres and hospitals compared. *J Int AIDS Soc* 2013; **16**: 18616.

37 Rasschaert F, Koole O, Zachariah R, Lynen L, Manzi M, Van Damme W. Short and long term retention in antiretroviral care in health facilities in rural Malawi and Zimbabwe. *BMC Health Serv Res* 2012; **12**: 444.

38 Le Paih M. Scale up impact on care access and early program attrition: seven years of providing ART in rural Malawi. *5th IAS Conf HIV Pathog Treat* 2009; **WEAD104**.

39 Jahn A. Monitoring retention and mortality in Malawi’s National ART Programme: improved outcomes with earlier treatment initiation and decentralization of services. *AIDS 2010 - XVIII Int AIDS Conf* 2010; **MOAE0305**.

40 Brinkhof MWG, Dabis F, Myer L, *et al.* Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. *Bull World Health Organ* 2008; **86**: 559–67.

41 Palladino C, Briz V, Bellón JM, *et al.* Predictors of Attrition and Immunological Failure in HIV-1 Patients on Highly Active Antiretroviral Therapy from Different Healthcare Settings in Mozambique. *PLoS One* 2013; **8**: e82718.

42 Lambdin BH, Micek M a, Koepsell TD, *et al.* Patient volume, human resource levels, and attrition from HIV Treatment programs in central Mozambique. *J Acquir Immune Defic Syndr* 2011; **57**: e33–9.

43 Micek M a, Gimbel-Sherr K, Baptista AJ, *et al.* Loss to follow-up of adults in public HIV care systems in central Mozambique: identifying obstacles to treatment. *J Acquir Immune Defic Syndr* 2009; **52**: 397–405.

44 Ehmer J. Patient characteristics and antiretroviral treatment outcomes in a very rural setting in Northern Moçambique, without access to second line. *6th IAS Conf HIV Pathog Treat* 2011; **CDD127**.

45 Moon TD. Predictors of adult mortality and loss-to-follow-up within two years of initiation of combination antiretroviral therapy in rural Mozambique. *19th Int AIDS Conf* 2012; **MOPE117**.

46 Wandeler G, Keiser O, Pfeiffer K, *et al.* Outcomes of Antiretroviral Treatment Programs in Rural Southern Africa. *J Acquir Immune Defic Syndr* 2012; **59**: 9–16.

47 Shepherd BE, Blevins M, Vaz LME, *et al.* Impact of definitions of loss to follow-up on estimates of retention, disease progression, and mortality: application to an HIV program in Mozambique. *Am J Epidemiol* 2013; **178**: 819–28.

48 Odafe S, Idoko O, Badru T, *et al.* Patients’ demographic and clinical characteristics and level of care associated with lost to follow-up and mortality in adult patients on first-line ART in Nigerian hospitals. *J Int AIDS Soc* 2012; **15**: 17424.

49 Onoka C a, Uzochukwu BS, Onwujekwe OE, *et al.* Retention and loss to follow-up in antiretroviral treatment programmes in southeast Nigeria. *Pathog Glob Health* 2012; **106**: 46–54.

50 Charurat M, Oyegunle M, Benjamin R, *et al.* Patient retention and adherence to antiretrovirals in a large antiretroviral therapy program in Nigeria: a longitudinal analysis for risk factors. *PLoS One* 2010; **5**: e10584.

51 Akinwande O. Facility-level variation in outcomes among ART cohorts in Nigeria. *6th IAS Conf HIV Pathog Treat* 2011; **CDD111**.

52 Franke MF, Kaigamba F, Socci AR, *et al.* Improved retention associated with community-based accompaniment for antiretroviral therapy delivery in rural Rwanda. *Clin Infect Dis* 2013; **56**: 1319–26.

53 Diouf A. Long-term efficacy of HAART among adult patients receiving ART in Senegal: a twelve years cohort study. *6th IAS Conf HIV Pathog Treat* 2011; **CDB340**.

54 Nglazi MD, Lawn SD, Kaplan R, *et al.* Changes in Programmatic Outcomes During 7 Years of Scale-up at a Community-Based Antiretroviral Treatment Service in South Africa. *J Acquir Immune Defic Syndr* 2011; **56**: 1–8.

55 Fatti G, Meintjes G, Shea J, Eley B, Grimwood A. Improved Survival and Antiretroviral Treatment Outcomes in Adults Receiving Community-Based Adherence Support: 5-Year Results From a Multicentre Cohort Study in South Africa. *JAIDS* 2012; **61**: 50–8.

56 Kranzer K, Lewis JJ, Ford N, *et al.* Treatment interruption in a primary care antiretroviral therapy program in South Africa: cohort analysis of trends and risk factors. *J Acquir Immune Defic Syndr* 2010; **55**: e17–23.

57 Buhlungu N. Five year follow up of clients receiving ART in resource poor setting of Umlazi Township in South Africa. *AIDS 2008 - XVII Int AIDS Conf* 2008; **CDB0239**.

58 Dahab M, Kielmann K, Charalambous S, *et al.* Contrasting reasons for discontinuation of antiretroviral therapy in workplace and public-sector HIV programs in South Africa. *AIDS Patient Care STDS* 2011; **25**: 53–9.

59 Innes C, Hamilton R, Hoffmann CJ, *et al.* A novel HIV treatment model using private practitioners in South Africa. *Sex Transm Infect* 2012; **88**: 136–40.

60 Peltzer K, Ramlagan S, Khan MS, Gaede B. The social and clinical characteristics of patients on antiretroviral therapy who are “lost to follow-up” in KwaZulu-Natal, South Africa: a prospective study. *SAHARA J* 2011; **8**: 179–86.

61 Searle CM et al. Using a file audit as a means of strengthening record keeping, improving quality of care & monitoring adherence at a public sector ARV site in KwaZulu-Natal, South Africa. *5th IAS Conf HIV Pathog Treat* 2009; **TUPED154**.

62 Hoffmann CJ, Fielding KL, Johnston V, *et al.* Changing predictors of mortality over time from cART start: implications for care. *J Acquir Immune Defic Syndr* 2011; **58**: 269–76.

63 Osler M. Despite increased burden due to scale-up, ART programme retention remains high in the Western Cape. *5th IAS Conf HIV Pathog Treat* 2009; **MOPED048**.

64 Evans D, Menezes C, Mahomed K, *et al.* Treatment Outcomes of HIV-Infected Adolescents Attending Public-Sector HIV Clinics Across Gauteng and Mpumalanga, South Africa. *AIDS Res Hum Retroviruses* 2013; **29**: 892–900.

65 Van Cutsem G, Ford N, Hildebrand K, *et al.* Correcting for mortality among patients lost to follow up on antiretroviral therapy in South Africa: a cohort analysis. *PLoS One* 2011; **6**: e14684.

66 Clouse K, Pettifor A, Maskew M, *et al.* Initiating antiretroviral therapy when presenting with higher CD4 cell counts results in reduced loss to follow-up in a resource-limited setting. *AIDS* 2013; **27**: 645–50.

67 MacPherson P, Moshabela M, Martinson N, Pronyk P. Mortality and loss to follow-up among HAART initiators in rural South Africa. *Trans R Soc Trop Med Hyg* 2009; **103**: 588–93.

68 Barth RE, van der Meer JTM, Hoepelman a IM, *et al.* Effectiveness of highly active antiretroviral therapy administered by general practitioners in rural South Africa. *Eur J Clin Microbiol Infect Dis* 2008; **27**: 977–84.

69 Fox M, Shearer K, Maskew M, *et al.* Treatment outcomes after 7 years of public-sector HIV treatment. *AIDS* 2012; **26**: 1823–8.

70 Khan MS. Retention and attrition of patients commenced on HAART at Ladysmith Provincial Hospital in South Africa. *5th IAS Conf HIV Pathog Treat* 2009; **MOPEB045**.

71 Ojikutu B, Zheng H, Walensky R, Lu Z, Losina E, Giddy J. Predictors of mortality in patients initiating antiretroviral therapy in Durban, South Africa. *South African Med J* 2008; **98**: 204–8.

72 Vella V, Govender T, Dlamini S, *et al.* Retrospective study on the critical factors for retaining patients on antiretroviral therapy in KwaZulu-Natal, South Africa. *J Acquir Immune Defic Syndr* 2010; **55**: 109–16.

73 Nachega JB, Hislop M, Dowdy DW, *et al.* Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults. *AIDS* 2008; **22**: 2117–25.

74 Mutevedzi PC, Lessells RJ, Newell M-L. Disengagement from care in a decentralised primary health care antiretroviral treatment programme: cohort study in rural South Africa. *Trop Med Int Heal* 2013; **18**: 934–41.

75 Ahonkhai A a, Noubary F, Munro A, *et al.* Not all are lost: interrupted laboratory monitoring, early death, and loss to follow-up (LTFU) in a large South African treatment program. *PLoS One* 2012; **7**: e32993.

76 Takuva S, Evans D, Zuma K, Okello V, Louwagie G. Comparative durability of nevirapine versus efavirenz in first-line regimens during the first year of initiating antiretroviral therapy among Swaziland HIV-infected adults. *Pan Afr Med J* 2013; **15**: 5.

77 Mossdorf E, Stoeckle M, Mwaigomole EG, *et al.* Improved antiretroviral treatment outcome in a rural African setting is associated with cART initiation at higher CD4 cell counts and better general health condition. *BMC Infect Dis* 2011; **11**: 98.

78 Kilama B, Todd J, Ewings F, Josiah R, Ramadhani A, Mmbando D. Tanzanian experience: treatment outcomes after 7 years of a national public­-driven HIV care and treatment program. *IAS 2013 Conf* 2013; **Abstract T**: 4–5.

79 Johannessen A, Naman E, Ngowi BJ, *et al.* Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania. *BMC Infect Dis* 2008; **8**: 52.

80 Hawkins C, Chalamilla G, Okuma J, *et al.* Sex differences in antiretroviral treatment outcomes among HIV-infected adults in an urban Tanzanian setting. *AIDS* 2011; **25**: 1189–97.

81 Saka B, Landoh DE, Patassi A, *et al.* Loss of HIV-infected patients on potent antiretroviral therapy programs in Togo: risk factors and the fate of these patients. *Pan Afr Med J* 2013; **15**: 35.

82 Bajunirwe F, Arts EJ, Tisch DJ, King CH, Debanne SM, Sethi AK. Adherence and treatment response among HIV-1-infected adults receiving antiretroviral therapy in a rural government hospital in Southwestern Uganda. *J Int Assoc Physicians AIDS Care (Chic)* 2009; **8**: 139–47.

83 Funk A, Kanters S, Nansubuga M, *et al.* Cohort profile: the MUg Observational Cohort. *Int J Epidemiol* 2012; **41**: 1594–1594f.

84 Geng EH, Glidden D V, Bwana MB, *et al.* Retention in care and connection to care among HIV-infected patients on antiretroviral therapy in Africa: estimation via a sampling-based approach. *PLoS One* 2011; **6**: e21797.

85 Mills EJ, Bakanda C, Birungi J, *et al.* Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy: evidence from a large cohort in Uganda. *AIDS* 2011; **25**: 851–5.

86 Kiragga AN, Castelnuovo B, Musomba R, *et al.* Comparison of Methods for Correction of Mortality Estimates for Loss to Follow-Up after ART Initiation: A Case of the Infectious Diseases Institute, Uganda. *PLoS One* 2013; **8**: e83524.

87 Mudiope PK, Kim S, Wabwire D, *et al.* Long-term clinical and immunologic outcomes of HIV-infected women with and without previous exposure to nevirapine. *Trop Med Int Health* 2013; **18**: 344–51.

88 Burkey MD, Weiser SD, Fehmie D, *et al.* Socioeconomic determinants of mortality in HIV: evidence from a clinical cohort in Uganda. *J Acquir Immune Defic Syndr* 2013. doi:10.1097/QAI.0000000000000094.

89 Namuwenge N. Temporal trends in baseline characteristics and treatment outcomes among clients initiating antiretroviral therapy in Uganda, 2005-2010. *19th Int AIDS Conf* 2012; **WEPE126**.

90 Torpey KE, Kabaso ME, Mutale LN, *et al.* Adherence support workers: a way to address human resource constraints in antiretroviral treatment programs in the public health setting in Zambia. *PLoS One* 2008; **3**: e2204.

91 Schöni-Affolter F, Keiser O, Mwango A, *et al.* Estimating loss to follow-up in HIV-infected patients on antiretroviral therapy: the effect of the competing risk of death in Zambia and Switzerland. *PLoS One* 2011; **6**: e27919.

92 Moyo C. Quality of ART services in rural Zambia after the rapid expansion of ART through task-shifting: are we providing quality care? *6th IAS Conf HIV Pathog Treat* 2011; **CDD016**.

93 Bygrave H, Mtangirwa J, Ncube K, Ford N, Kranzer K, Munyaradzi D. Antiretroviral therapy outcomes among adolescents and youth in rural Zimbabwe. *PLoS One* 2012; **7**: e52856.

94 Mutasa-Apollo T, Shiraishi RW, Takarinda KC, *et al.* Patient retention, clinical outcomes and attrition-associated factors of HIV-infected patients enrolled in Zimbabwe’s National Antiretroviral Therapy Programme, 2007-2010. *PLoS One* 2014; **9**: e86305.

95 Van Griensven J, Thai S. Predictors of immune recovery and the association with late mortality while on antiretroviral treatment in Cambodia. *Trans R Soc Trop Med Hyg* 2011; **105**: 694–703.

96 Argemi X, Dara S, You S, *et al.* Impact of malnutrition and social determinants on survival of HIV-infected adults starting antiretroviral therapy in resource-limited settings. *AIDS* 2012; **26**: 1161–6.

97 Morineau G, Vun MC, Barennes H, *et al.* Survival and quality of life among HIV-positive people on antiretroviral therapy in Cambodia. *AIDS Patient Care STDS* 2009; **23**: 669–77.

98 Pujades-Rodríguez M, Schramm B, Som L, *et al.* Immunovirological outcomes and resistance patterns at 4 years of antiretroviral therapy use in HIV-infected patients in Cambodia. *Trop Med Int Health* 2011; **16**: 205–13.

99 Zhu H, Napravnik S, Eron J, *et al.* Attrition among human immunodeficiency virus (HIV)- infected patients initiating antiretroviral therapy in China, 2003-2010. *PLoS One* 2012; **7**: e39414.

100 Spillane H, Nicholas S, Tang Z, Szumilin E, Balkan S, Pujades-Rodriguez M. Incidence, risk factors and causes of death in an HIV care programme with a large proportion of injecting drug users. *Trop Med Int Heal* 2012; **17**: 1255–63.

101 McMahon JH, Manoharan A, Wanke C, *et al.* Targets for intervention to improve virological outcomes for patients receiving free antiretroviral therapy in Tamil Nadu, India. *AIDS Care* 2013.http://www.ncbi.nlm.nih.gov/pubmed/24125035 (accessed 11 Jan2014).

102 Hingankar NK, Thorat SR, Deshpande A, *et al.* Initial virologic response and HIV drug resistance among HIV-infected individuals initiating first-line antiretroviral therapy at 2 clinics in Chennai and Mumbai, India. *Clin Infect Dis* 2012; **54 Suppl 4**: S348–54.

103 Sharma SK, Dhooria S, Prasad KT, *et al.* Outcomes of antiretroviral therapy in a northern Indian urban clinic. *Bull World Health Organ* 2010; **88**: 222–6.

104 Rewari B, Raj S. Two-year treatment outcomes of the first-line antiretroviral therapy programme in India. *AIDS 2008 - XVII Int AIDS Conf* 2008; **MOPE0054**.

105 Rai S, Mahapatra B, Sircar S, *et al.* Adherence to Antiretroviral Therapy and Its Effect on Survival of HIV-Infected Individuals in Jharkhand, India. *PLoS One* 2013; **8**: e66860.

106 Ghate M, Tripathy S, Gangakhedkar R, *et al.* Use of first line antiretroviral therapy from a free ART programme clinic in Pune, India - a preliminary report. *Indian J Med Res* 2013; **137**: 942–9.

107 Chadha S, Bhalla P, Jha AK, Gautam H, Saini S, Anuradha S. Disease progression and antiretroviral therapy in newly seropositive HIV subjects in a tertiary care hospital in North India. *J Infect Dev Ctries* 2013; **7**: 110–5.

108 Alvarez-Uria G, Naik PK, Pakam R, Midde M. Factors associated with attrition, mortality, and loss to follow up after antiretroviral therapy initiation: data from an HIV cohort study in India. *Glob Health Action* 2013; **6**: 21682.

109 Wisaksana R, Indrati AK, Fibriani A, *et al.* Response to first-line antiretroviral treatment among human immunodeficiency virus-infected patients with and without a history of injecting drug use in Indonesia. *Addiction* 2010; **105**: 1055–61.

110 Bastard M, Soulinphumy K, Phimmasone P, *et al.* Women experience a better long-term immune recovery and a better survival on HAART in Lao People’s Democratic Republic. *BMC Infect Dis* 2013; **13**: 27.

111 Sabapathy K, Ford N, Chan KN, *et al.* Treatment outcomes from the largest antiretroviral treatment program in Myanmar (Burma): a cohort analysis of retention after scale-up. *J Acquir Immune Defic Syndr* 2012; **60**: e53–62.

112 Bhatta L, Klouman E, Deuba K, *et al.* Survival on antiretroviral treatment among adult HIV-infected patients in Nepal: a retrospective cohort study in far-western Region, 2006-2011. *BMC Infect Dis* 2013; **13**: 604.

113 Das S, Carmone A, Franke MF, *et al.* Retention Amongst Art Patients in the Highlands of Papua New Guinea: Evaluating the Papua Model. *J Acquir Immune Defic Syndr* 2013. doi:10.1097/QAI.0b013e3182a14f7e.

114 Ruxrungtham K, Avihingsanon A, Pinyakorn S, *et al.* Excellent outcomes of the Thailand national antiretroviral treatment universal coverage program in over 200,000 HIV­ infected adults. *IAS 2013 Conf* 2013; **Abstract M**: 1–2.

115 Le Y, Do N, Nguyen DB, *et al.* Poorer antiretroviral therapy outcomes in HIV infected injecting drug users in Vietnam. *AIDS 2010 - XVIII Int AIDS Conf* 2010; **CDB0136**.

116 Duong B. Application of ART cohort analysis and HIV drug resistance early warning indicators as tools to monitor HIV/AIDS care and treatment program in Viet Nam. *AIDS 2010 - XVIII Int AIDS Conf* 2010; **CDC0508**.

117 Nguyen DB, Do NT, Shiraishi RW, *et al.* Outcomes of antiretroviral therapy in Vietnam: results from a national evaluation. *PLoS One* 2013; **8**: e55750.

118 Tuboi SH, Schechter M, McGowan CC, *et al.* Mortality during the first year of potent antiretroviral therapy in HIV-1-infected patients in 7 sites throughout Latin America and the Caribbean. *J Acquir Immune Defic Syndr* 2009; **51**: 615–23.

119 Cardoso SW, Grinsztejn B, Velasque L, *et al.* Incidence of modifying or discontinuing first HAART regimen and its determinants in a cohort of HIV-infected patients from Rio de Janeiro, Brazil. *AIDS Res Hum Retroviruses* 2010; **26**: 865–74.

120 Koenig SP, Rodriguez LA, Bartholomew C, *et al.* Long-Term Antiretroviral Treatment Outcomes in Seven Countries in the Caribbean. *J Acquir Immune Defic Syndr* 2012; **59**: 60–71.

121 Halpern M, Lachmansingh B, Minior T, Hasbrouck LM, Persaud N, Foo A. Implementation of a standardized HIV patient monitoring system in Guyana. *Rev Panam Salud Publica* 2010; **28**: 107–13.

122 Shakir F. Early mortality of HIV-patients on ART from a low-prevalence country in Latin America: results from Nicaragua. *AIDS 2010 - XVIII Int AIDS Conf* 2010; **THPE0417**.

123 Muñoz M, Finnegan K, Zeladita J, *et al.* Community-based DOT-HAART accompaniment in an urban resource-poor setting. *AIDS Behav* 2010; **14**: 721–30.